NCT01781572 - A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

January 15, 2018

Study Completion Date

February 20, 2018

Conditions

Locally Advanced or Metastatic NRAS Mutant Melanoma

Interventions

DRUG

LEE011

LEE011 will be administered orally once daily

DRUG

MEK162

MEK162 will be administered orally twice daily

Trial Locations (17)

2060

Pfizer Investigative Site 1003, North Sydney

2145

Pfizer Investigative Site 1002, Westmead

10021

Memorial Sloan Kettering Cancer Center Dept Oncology, New York

10032

Columbia University Medical Center- New York Presbyterian Onc Dept., New York

30625

Pfizer Investigative Site 1052, Hanover

37232

Vanderbilt University Medical Center SC - Dept of Oncology ., Nashville

45147

Pfizer Investigative Site 1050, Essen

48201

Karmanos Cancer Institute Dept of Oncology, Detroit

80131

Pfizer Investigative Site 1101, Napoli

80336

Pfizer Investigative Site 1051, München

94101

University of California, Dept of Oncology, San Francisco

94120-7999

California Pacific Medical Center Onc Dept, San Francisco

77030-4009

University of Texas/MD Anderson Cancer Center Dept of Onc., Houston

Unknown

Pfizer Investigator Site 1001, East Melbourne

07548

Pfizer Investigative Site 1053, Gera

3508 GA

Pfizer Investigative Site 1151, Utrecht

6525 GA

Pfizer Investigative Site 1150, Nijmegen